Adjuvant effect of CIA07, a combination of Escherichia coli DNA fragments and modified lipopolysaccharides, on the immune response to hepatitis B virus surface antigen

FEMS Immunology and Medical Microbiology

Volumn 51, Issue 3, 2007, Pages 496-504

  Song, Eun Sun ^a   Park, Shin Ae ^a   Kim, Su Hee ^a   Cho, Yang Je ^b   Ahn, Bo Young ^b   Ahn, Byung Cheol ^c   Lee, Na Gyong ^a  

^a Sejong University   (South Korea)

^b EyeGene Inc   (South Korea)

^c Dobeel Corporation   (South Korea)

Author keywords

Adjuvant; Antibody response; Cellular immune response; Hepatitis B surface antigen

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CIA07 ADJUVANT; CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE 1826; DNA FRAGMENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, SURFACE; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DNA, BACTERIAL; ESCHERICHIA COLI; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INTERFERON TYPE II; LIPOPOLYSACCHARIDES; LYMPHOCYTES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SPLEEN; TH1 CELLS;

EID: 35948983800     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2007.00325.x     Document Type: Article

References (33)

1. Aguilar JC Rodriguez EG (2007) Vaccine adjuvants revisited. Vaccine 25 : 3752 3762.
2. Akira S, Takeda K Kaisho T (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408 : 740 745.
3. Alving CR (1993) Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiology 187 : 430 446.
4. Ballas ZK, Rasmussen WL Krieg AM (1996) Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157 : 1840 1845.
5. Bertok L (2005) Radio-detoxified endotoxin activates natural immunity: a review. Pathophysiology 12 : 85 95.
6. Cho YJ, Ahn BY, Lee NG, Lee DH Kim DS (2006) A combination of E. coli DNA fragments and modified lipopolysaccharides as a cancer immunotherapy. Vaccine 24 : 5862 5871.
7. Cho YJ, Ahn BY, Song ES, Park SA, Lee DH, Kim DS Lee NG (2007) Bacterial DNA containing methylated CpG motifs retains immunostimulatory activity in synergy with modified lipopolysaccharides. Microbiol Immunol 51 : 211 222.
8. Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW Heathcote J (2004a) CpG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24 : 693 701.
9. Cooper CL, Davis HL, Morris ML et al 2004b) Safety and immunogenicity of CpG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22 : 3136 3143.
10. Cowdery JS, Chace JH, Yi AK Krieg AM (1996) Bacterial DNA induces NK cells to produce interferon gamma in vivo and increases the toxicity of lipopolysaccharide. J Immunol 156 : 4570 4575.
11. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J Krieg AM (1998) CpG DNA is potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160 : 870 876.
12. Di Pauli R (1972) Genetics of the immune response. I. Differences in the specificity of antibodies to lipopolysaccharides among different strains of mice. J Immunol 109 : 394 400.
13. Freidag BL, Melton GB, Collins F, Klinman DM, Cheever A, Stobie L, Suen W Seder RA (2000) CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. Tuberculosis. Infect Immun 68 : 2948 2953.
14. Gao JJ, Xue Q, Papasian CJ Morrison DC (2001) Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-alpha through a post-transcriptional mechanism. J Immunol 166 : 6855 6860.
15. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdorfer B, Krug A, Rothenfusser S, Endres S Hartmann G (2002) Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 169 : 3892 3899.
16. Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20 : 709 760.
17. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA Klinman DM (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 : 546 549.
18. Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11 : 97 107.
19. Lee CH Tsai CM (1999) Quantification of bacterial lipopolysaccharides by the purpald assay: measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation. Anal Biochem 267 : 161 168.
20. Milas L, Mason KA, Ariga H, Hunter N, Neal R, Valdecanas D, Krieg AM Whisnant JK (2004) CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 64 : 5074 5077.
21. Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, Bennett CF Crooke ST (1997) Immune stimulation-a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des 12 : 421 432.
22. Otto F, Schmid P, Mackensen A, Wehr U, Seiz A, Braun M, Galanos C, Mertelsmann R Engelhardt R (1996) Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur J cancer 32A : 1712 1718.
23. Pichyangkul S, Yongvanitchit K, Kum-arb U, Krieg AM, Heppner DG Wals DS (2001) Whole blood cultures to assess the immunostimulatory activities of CpG oligodeoxynucleotides. J Immunol Methods 247 : 83 94.
24. Roberts TL, Dunn JA, Terry TD, Jennings MP, Hume DA, Sweet MJ Stacey KJ (2005) Differences in macrophage activation by bacterial DNA and CpG-containing oligonucleotides. J Immunol 175 : 3569 3576.
25. Schirmbeck R, Wild J Reimann J (1998) Similar as well as distinct MHC class-I binding peptides are generated by exogenous and endogenous processing of hepatitis B virus surface antigen. Eur J Immunol 28 : 4149 4161.
26. Shimada S, Yano O Tokunaga T (1986) In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG. Jpn J Cancer Res 77 : 808 816.
27. Sparwasser T, Koch ES, Vabulas RM, Heeg K, Lipford GB, Ellwart JW Wagner H (1998) Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 28 : 2045 2054.
28. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC Romero P (2005) Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115 : 739 746.
29. Stacey KJ Blackwell JM (1999) Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun 67 : 3719 3726.
30. Stacy KJ, Sweet MJ Hume DA (1996) Macrophages ingest and are activated by bacterial DNA. J Immunol 157 : 2116 2122.
31. Weigel BJ, Rodeberg DA, Krieg AM Blazar BR (2003) CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 9 : 3105 3114.
32. Weiner GJ (2000) Immunostimulatory DNA sequences and cancer therapy. Springer Semin Immunopathol 22 : 107 116.
33. Yamamoto S, Yamamoto T, Shimada S, Kuramoto E, Yano O, Kataoka T Tokunaga T (1992) DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol 36 : 983 997.